ERBB2 and breast cancer: ERBB2-targeted therapies such as anti-ERBB2 antibodies (such as trastuzumab or pertuzumab) or tyrosine kinase inhibitors (such as lapatinib and neratinib) have been successfully used against these types of breast cancers [2,3].